Peginterferon Alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites

Peginterferon Alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites

Black patients with chronic hepatitis C have a higher prevalence of genotype 1 infection and a lower rate of response to treatment. In this prospective study of 100 black and 100 non-Hispanic white patients with chronic hepatitis C (98 percent genotype 1), black patients had a lower rate of response...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2004-05, Vol.350 (22), p.2265-2271
Hauptverfasser: Muir, Andrew J, Bornstein, Jeffrey D, Killenberg, Paul G
Format: Artikel
Sprache:eng
Schlagworte:
Adult
African Americans
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Autoimmune diseases
Biological and medical sciences
Drug Therapy, Combination
European Continental Ancestry Group
Female
General aspects
Genotype
Genotype & phenotype
Hepacivirus - genetics
Hepatitis
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - ethnology
Hepatitis C, Chronic - virology
Hispanic people
Human viral diseases
Humans
Infectious diseases
Interferon-alpha - adverse effects
Interferon-alpha - therapeutic use
Logistic Models
Male
Medical sciences
Middle Aged
Multivariate Analysis
Patients
Polyethylene Glycols
Prospective Studies
Recombinant Proteins
Ribavirin - adverse effects
Ribavirin - therapeutic use
RNA, Viral - blood
Socioeconomic Factors
Viral diseases
Viral hepatitis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Black patients with chronic hepatitis C have a higher prevalence of genotype 1 infection and a lower rate of response to treatment. In this prospective study of 100 black and 100 non-Hispanic white patients with chronic hepatitis C (98 percent genotype 1), black patients had a lower rate of response to treatment with peginterferon alfa-2b and ribavirin (19 percent vs. 52 percent, P
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa032502